⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Since Ozempic and Mounjaro became widely discussed in India — through social media, WhatsApp forwards, and celebrity weight-loss stories — an enormous amount of misinformation has spread. Some myths discourage people who would genuinely benefit from treatment. Others create false expectations that lead to disappointment. This guide addresses the most common myths Indian patients encounter.
Consult your healthcare provider before starting any medication. Individual responses to GLP-1 medications vary significantly.
Fact: Diet and exercise alone produce average long-term weight loss of 3–5% body weight with high relapse rates. Semaglutide 2.4 mg (Wegovy) produces an average of 14.9% body weight loss over 68 weeks in clinical trials (STEP 1), with some participants losing over 20%. Tirzepatide (Mounjaro) shows even stronger results — 20.9% average weight loss in the SURMOUNT-1 trial.
More importantly, GLP-1 medications address the biological drivers of obesity — altered satiety hormones, elevated hunger-signalling in the brain, and impaired metabolic regulation — that make sustained weight loss through willpower alone extremely difficult for most people.
The combination of GLP-1 medication with diet and exercise produces significantly better results than any single approach. GLP-1 is a medical treatment for a recognised disease, not a shortcut.
Fact: This myth has two layers worth unpacking.
First, semaglutide exists in multiple formulations for different indications:
Second, the same molecule (semaglutide) is used for both conditions — the indication and dose differ, not the safety profile. Doctors in India legally and appropriately prescribe Ozempic off-label for weight management in non-diabetic patients with obesity, as permitted under Indian medical practice guidelines.
Tirzepatide (Mounjaro) similarly has approval for diabetes and emerging evidence for obesity treatment.
Fact: This is partially outdated and largely incorrect.
What IS true: Wegovy (the high-dose weight-loss formulation of semaglutide) has more limited availability in India compared to the US or UK. Some states have intermittent supply issues. But the medications are not "banned" — they are prescription drugs requiring a doctor's prescription, which is appropriate.
Beware of social media posts claiming medications are "imported from abroad" or "unavailable in India" as justification for selling unverified products. Always buy from licensed pharmacies.
Fact: Weight regain after discontinuing GLP-1 medications is real — but "immediately" and "all of it" are exaggerations that require nuance.
The STEP 4 trial (semaglutide withdrawal study) found that participants who stopped semaglutide regained about two-thirds of their lost weight within 1 year of stopping. This confirms that GLP-1 medications treat obesity as a chronic condition — much like blood pressure medications treat hypertension. Stopping treatment typically requires careful planning with your doctor, including transitioning to lifestyle interventions that can maintain some of the metabolic benefits.
However, several factors influence post-cessation outcomes:
The goal of GLP-1 therapy should include building sustainable habits during treatment, not just losing weight.
Fact: This myth originates from a genuine but often misrepresented warning in GLP-1 prescribing information.
In rodent studies at high doses, GLP-1 receptor agonists caused C-cell thyroid tumours (medullary thyroid carcinoma, or MTC). However:
For the general population without these specific risk factors, the thyroid cancer risk from GLP-1 medications is theoretical, not clinically established. Your doctor will screen for contraindications before prescribing.
Fact: GLP-1 medications are powerful metabolic tools, but they are not calorie-ignorant. The mechanism works by reducing appetite and slowing gastric emptying — which helps you eat less. But:
GLP-1 medications make it easier to eat less — they do not ensure you eat well. Indian patients who take the medication seriously and improve their dietary quality consistently achieve better and more durable outcomes.
Fact: Eligibility criteria in clinical guidelines (not just "very obese") include:
| Criteria | Threshold |
|---|---|
| BMI | ≥30 kg/m² (obesity) |
| BMI with comorbidities | ≥27 kg/m² with Type 2 diabetes, hypertension, dyslipidaemia, or sleep apnoea |
| Asian Indian adjustment | Many guidelines recommend using 25 kg/m² (obesity) and 23 kg/m² (overweight) thresholds for South Asians |
Indian-origin populations have higher body fat percentage at lower BMI values compared to Western populations — a well-established finding across multiple ICMR and WHO studies. An Indian patient at BMI 27 with Type 2 diabetes often has similar metabolic risk to a Western patient at BMI 32.
Discuss eligibility with your doctor based on your full clinical picture, not just a BMI number.
Fact: The evidence shows the opposite.
Cardiovascular: The SUSTAIN-6 trial (semaglutide) showed a 26% reduction in major adverse cardiovascular events (MACE) compared to placebo in high-risk patients. The SELECT trial (semaglutide in non-diabetic adults with obesity and cardiovascular disease) confirmed cardiovascular benefit. Far from damaging the heart, GLP-1 medications have emerged as a major cardiovascular protective treatment.
Kidneys: The FLOW trial (2024) demonstrated that semaglutide significantly reduced kidney disease progression and cardiovascular death in patients with Type 2 diabetes and chronic kidney disease — a landmark finding now shaping nephrology practice globally.
The rare genuine risks (pancreatitis risk in susceptible individuals, gallbladder effects) exist but are unrelated to kidneys or the heart.
Fact: Self-prescribing GLP-1 medications without medical supervision carries significant risks:
GLP-1 medications require a doctor's prescription in India for good reason. The consultation process screens for contraindications, establishes baseline labs, and provides the dose escalation guidance that prevents the worst side effects.
Fact: This myth is not supported by evidence. While most large trials were conducted in Western populations, Indian-specific data is growing:
Indian bodies respond to GLP-1 medications. The adjustments needed are in dosing, dietary context (adapting advice to Indian foods), and BMI thresholds (lower cutoffs for Asian Indians).
If you have heard a specific claim about GLP-1 medications — positive or negative — and are unsure whether it is true, bring it up at your next consultation. Indian endocrinologists and diabetologists familiar with GLP-1 therapy can address concerns specific to your clinical situation.
Do not rely on YouTube videos, WhatsApp forwards, or social media testimonials as your primary source of medical information.
Frequently Asked Questions
Q: Is it safe to take GLP-1 if I have fatty liver (NAFLD)? A: Emerging evidence strongly suggests GLP-1 medications benefit fatty liver disease. The ESSENCE trial (semaglutide in NASH) showed significant improvement in liver histology. Discuss with your hepatologist or endocrinologist.
Q: Can I take GLP-1 with Ayurvedic medicines? A: Some Ayurvedic preparations may affect blood glucose. Always disclose all Ayurvedic, herbal, or home remedies to your prescribing doctor. Do not assume "natural = safe to combine."
Q: Will my insurance cover GLP-1 medications in India? A: Most Indian health insurance policies do not currently cover GLP-1 medications for weight loss. Some policies cover them for Type 2 diabetes. Verify with your insurer before assuming coverage.
Q: How long do I need to stay on GLP-1 medications? A: GLP-1 medications treat a chronic condition. Most guidelines recommend ongoing treatment, not a fixed course. Your doctor will assess when (and if) to consider dose reduction or discontinuation based on your response and goals.
